Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pigment epithelium-derived factor, an anti-VEGF factor, delays ovarian cancer progression by alleviating polarization of tumor-associated macrophages

Cancer Gene Therapyvolume29,pages1332–1341 (2022)Cite this article

Subjects

Abstract

卵巢癌(OC)是一种最危险的gynecological malignancies with no effective treatment so far. Pigment epithelium-derived factor (PEDF) has been reported to have ideal anti-tumor effects, but its relationship with the regulation of tumor-associated macrophage polarization is currently unclear. In this study, the mRNA expression of PEDF and macrophage markers were determined in OC tissues from clinic patients and five OC (A2780, SKOV3, CAOV3, OVCAR3, and OVCA433) cell lines through quantitative reverse transcription PCR. Afterwards, tumor growth, cell proliferation and apoptosis, and macrophage polarization in OC tumor-bearing mice with PEDF overexpression were recorded and investigated. Finally, the polarization of macrophages was explored in the presence of lentiviral PEDF overexpression, adipose triglyceride lipase (ATGL) and laminin receptor (LR) knockdown, and mitogen-activated protein kinase (MAPK) pathway inhibition. Our results suggest that PEDF mRNA level is significantly decreased in OC tissues and cells and has a significant negative correlation with OC progression and the level of tumor-related macrophage markers. Furthermore, OC tumors overexpressing PEDF show suppressed growth viability and increased apoptosis rate. The fluorescence activated cell sorting (FACS) analysis reveals that PEDF can promote macrophage polarization in OC tumors towards M1 subtype. Mechanistically, we found that ATGL and extracellular-regulated kinase 1/2 (ERK1/2) signaling are involved in the regulation of macrophage polarization in OC tumors by PEDF. Taken together, these data indicate that the role of PEDF in regulating the polarization of tumor-associated macrophages may make it a potential therapeutic strategy for the treatment of OC in the future.

This is a preview of subscription content,access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Fig. 1: Pigment epithelium-derived factor (PEDF) is down-regulated in ovarian cancer (OC) and correlates negatively with metastatic progression in OC patients.
Fig. 2: PEDF is associated with the polarization of macrophages in OC tissues and cells.
Fig. 3: PEDF slows OC progression in the tumor-bearing mice.
Fig. 4: PEDF decreases the polarization of tumor-associated M2 macrophages.
Fig. 5: PEDF modulates macrophage polarization through targeting adipose triglyceride lipase (ATGL) and extracellular-regulated kinase 1/2 (ERK1/2).

Data availability

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding authors.

References

  1. Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, et al. Current ovarian cancer maintenance strategies and promising new developments. J Cancer. 2021;12:38–53.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  2. 戴Chatterjee J, W,阿齐兹NHA Teo PY, Wahba J, Phelps DL, et al. Clinical use of programmed cell death-1 and its ligand expression as discriminatory and predictive markers in ovarian cancer. Clin Cancer Res. 2017;23:3453–60.

    ArticleCASPubMedGoogle Scholar

  3. Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 2013;33:137–64.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  4. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604.

    ArticleCASPubMedGoogle Scholar

  5. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229:176–85.

    ArticleCASPubMedGoogle Scholar

  6. Squadrito ML, De, Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol Asp Med. 2011;32:123–45.

    ArticleCASGoogle Scholar

  7. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  8. Laoui D, Van Overmeire E, Movahedi K, Van den Bossche J, Schouppe E, Mommer C, et al. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology. 2011;216:1192–202.

    ArticleCASPubMedGoogle Scholar

  9. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231–7.

    ArticleCASPubMedGoogle Scholar

  10. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.

    ArticleCASPubMedGoogle Scholar

  11. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7:e50946.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  12. Jiang B, Zhu SJ, Xiao SS, Xue M. MiR-217 inhibits M2-like macrophage polarization by suppressing secretion of interleukin-6 in ovarian cancer. Inflammation. 2019;42:1517–29.

    ArticlePubMedGoogle Scholar

  13. Ying X, Wu Q, Wu X, Zhu Q, Wang X, Jiang L, et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016;7:43076–87.

    ArticlePubMedPubMed CentralGoogle Scholar

  14. He X, Cheng R, Benyajati S, Ma JX. PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases. Clin Sci (Lond). 2015;128:805–23.

    ArticleGoogle Scholar

  15. Abe R, Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y, et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol. 2004;164:1225–32.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  16. Halin S, Wikstrom P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE, et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res. 2004;64:5664–71.

    ArticleCASPubMedGoogle Scholar

  17. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology. 2004;40:252–9.

    ArticleCASPubMedGoogle Scholar

  18. Johnston EK, Francis MK, Knepper JE. Recombinant pigment epithelium-derived factor PEDF binds vascular endothelial growth factor receptors 1 and 2. Vitr Cell Dev Biol Anim. 2015;51:730–8.

    ArticleCASGoogle Scholar

  19. Seki R, Yamagishi S, Matsui T, Yoshida T, Torimura T, Ueno T, et al. Pigment epithelium-derived factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties. Biochem Biophys Res Commun. 2013;431:693–7.

    ArticleCASPubMedGoogle Scholar

  20. Tsuruhisa S, Matsui T, Koga Y, Sotokawauchi A, Yagi M, Yamagishi SI. Pigment epithelium-derived factor inhibits advanced glycation end product-induced proliferation, VEGF and MMP-9 expression in breast cancer cells via interaction with laminin receptor. Oncol Lett. 2021;22:629.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  21. Takenaka K, Yamagishi S, Jinnouchi Y, Nakamura K, Matsui T, Imaizumi T. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci. 2005;77:3231–41.

    ArticleCASPubMedGoogle Scholar

  22. Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, et al. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11:1199–209.

    ArticleCASPubMedGoogle Scholar

  23. Cassetta L, Noy R, Swierczak A, Sugano G, Smith H, Wiechmann L, et al. Isolation of mouse and human tumor-associated macrophages. Adv Exp Med Biol. 2016;899:211–29.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  24. Pino PA, Cardona AE. Isolation of brain and spinal cord mononuclear cells using percoll gradients. J Vis Exp. 2011;2011:2348.

    Google Scholar

  25. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  26. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273–82.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  27. Bernard A, Gao-Li J, Franco CA, Bouceba T, Huet A, Li Z. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem. 2009;284:10480–90.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  28. Notari L, Baladron V, Aroca-Aguilar JD, Balko N, Heredia R, Meyer C, et al. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem. 2006;281:38022–37.

    ArticleCASPubMedGoogle Scholar

  29. Chavan SS, Hudson LK, Li JH, Ochani M, Harris Y, Patel NB, et al. Identification of pigment epithelium-derived factor as an adipocyte-derived inflammatory factor. Mol Med. 2012;18:1161–8.

    ArticleCASPubMedPubMed CentralGoogle Scholar

  30. Neamatallah T. Mitogen-activated protein kinase pathway: a critical regulator in tumor-associated macrophage polarization. J Microsc Ultrastruct. 2019;7:53–56.

    ArticlePubMedPubMed CentralGoogle Scholar

  31. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

    ArticlePubMedGoogle Scholar

  32. Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, et al. Epirubicin, cisplatin, and capecitabine for primary platinum-resistant or platinum-refractory epithelial ovarian cancer: results of a retrospective, single-institution study. Int J Gynecol Cancer. 2015;25:977–84.

    ArticlePubMedPubMed CentralGoogle Scholar

  33. Cheung LW, Au SC, Cheung AN, Ngan HY, Tombran-Tink J, Auersperg N, et al. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology. 2006;147:4179–91.

    ArticleCASPubMedGoogle Scholar

  34. Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP, et al. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res. 1996;56:606–11.

    CASPubMedGoogle Scholar

  35. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245–8.

    ArticleCASPubMedGoogle Scholar

  36. Maik-Rachline G, Shaltiel S, Seger R. Extracellular phosphorylation converts pigment epithelium-derived factor from a neurotrophic to an antiangiogenic factor. Blood. 2005;105:670–8.

    ArticleCASPubMedGoogle Scholar

  37. Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med. 2006;12:497–502.

    ArticleCASPubMedGoogle Scholar

  38. Becerra SP, Sagasti A, Spinella P, Notario V. Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. J Biol Chem. 1995;270:25992–9.

    ArticleCASPubMedGoogle Scholar

  39. 范Overmeire E, Laoui D, Keirsse J,范Ginderachter JA, Sarukhan A. Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol. 2014;5:127.

    PubMedPubMed CentralGoogle Scholar

  40. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    ArticleCASPubMedGoogle Scholar

  41. Rohan TE, Xue X, Lin HM, D'Alfonso TM, Ginter PS, Oktay MH, et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst. 2014;106:dju136.

    ArticlePubMedPubMed CentralGoogle Scholar

  42. Al-Zoughbi W, Pichler M, Gorkiewicz G, Guertl-Lackner B, Haybaeck J, Jahn SW, et al. Loss of adipose triglyceride lipase is associated with human cancer and induces mouse pulmonary neoplasia. Oncotarget. 2016;7:33832–40.

    ArticlePubMedPubMed CentralGoogle Scholar

  43. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24:x16–21. Suppl 10

    ArticlePubMedGoogle Scholar

  44. Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8:1093.

    ArticlePubMedPubMed CentralGoogle Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, School of Clinical Medicine of Nanjing Medical University, Shanghai, 200072, China

    Rui Ma, Xiaolin Chu & Yiting Jiang

  2. Department of Oncology, Shanghai Tenth People’s Hospital, School of Clinical Medicine of Nanjing Medical University, Shanghai, 200072, China

    Qing Xu

Authors
  1. Rui Ma
    View author publications

    You can also search for this author inPubMedGoogle Scholar

  2. Xiaolin Chu
    View author publications

    You can also search for this author inPubMedGoogle Scholar

  3. Yiting Jiang
    View author publications

    You can also search for this author inPubMedGoogle Scholar

  4. Qing Xu
    View author publications

    You can also search for this author inPubMedGoogle Scholar

Contributions

Design and experimentation: RM, XC, YJ, and QX; supervision: QX; and manuscript writing: RM and QX.

Corresponding author

Correspondence toQing Xu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics statement

The present study was approved by the Ethics Review Committee of Shanghai Tenth People’s Hospital. Written informed consent was obtained from all participants before specimen collection.

Additional information

Publisher’s noteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

验证货币和真实性via CrossMark

Cite this article

Ma, R., Chu, X., Jiang, Y.et al.Pigment epithelium-derived factor, an anti-VEGF factor, delays ovarian cancer progression by alleviating polarization of tumor-associated macrophages.Cancer Gene Ther29, 1332–1341 (2022). https://doi.org/10.1038/s41417-022-00447-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:https://doi.org/10.1038/s41417-022-00447-4

Search

Advanced search

Quick links

Baidu
map